PD-1 Agonists Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0140
Release Date: On the same day of purchase

PD-1 Agonists Pipeline Review

Target: PD-1 (programmed cell death protein-1)

Product Category: Antibody

This product provides basic information on antibody therapy candidates in research and development targeting PD-1.

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
  • Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for therapeutics and therapy candidates targeting PD-1 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Human programmed cell death protein-1 (PD-1) antagonist antibodies have become a clinically and commercially extremely successful cancer therapy. PD-1 (CD279) is a CD28/CTLA4 family coinhibitory receptor that is mainly found on activated lymphocytes. Ample evidence links the PD-1- pathway to autoimmune diseases, ranging from genetic evidence, correlations between PD-1 expression and disease severity in patients, and autoimmune-like immune-related adverse events (irAE) from blocking PD-1 pathway therapies in oncology. Consequently, the activation of the PD-1 pathway through agonist antibodies holds promise as a therapeutic approach in autoimmune disease.

Checkpoint agonism represents a promising and expanding class of therapies for the treatment of autoimmune diseases, including rheumatoid arthritis (RA). The characteristics that confer agonistic properties to an antibody targeting a checkpoint receptor is an evolving science. Suzuki et al. (2023) showed that PD-1 agonists exist in the group of anti-PD-1 antibodies recognizing the membrane-proximal extracellular region in sharp contrast to the binding of the membrane-distal region by blocking antibodies. Binding to membrane proximal regions of suppressive receptors, together with Fc interactions with receptors on opposing cells, can contribute to tight immune synapse formation between the immune cell and antigen presenting cell. This has been proposed to improve potency of agonistic signaling.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01